Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension
References
Additional references
Deeks JJ, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Egan BM, Li J, Shatat IF, Fuller JM, Sinopoli A. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation 2014;129(20):2052‐61.
Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin‐converting enzyme inhibition in patients with chronic heart failure. Current Cardiology Reports 2000;2(3):258‐62. [PUBMED: 10980901]
Epstein BJ, Leonard PT, Shah NK. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. Expert Review of Cardiovascular Therapy 2012;10(6):713‐25.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Practice guidelines for the management of arterial hypertension. Blood Pressure 2014;23(1):3‐16.
Ferrario CM. Importance of the renin‐angiotensin‐aldosterone system (RAS) in the physiology and pathology of hypertension. An overview. Drugs 1990;39(Suppl 2):1‐8.
Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD003823.pub2]
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Avaialble from handbook.cochrane.org. The Cochrane Collaboration.
James PA, Oparil S, Carter BL, Cushman WC, Dennison‐Himmelfarb C, Handler J, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507‐20.
Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009096.pub2]
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global burden and control of hypertension in 2010: Analysis of population‐based studies from 89 countries. Circulation. Conference: American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2015 Scientific Sessions Baltimore, MD United States. 2015; Vol. 131.
Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD007066.pub2]
Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio‐oedema. Lancet 1998;351(9117):1693‐7.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (editors). Chapter 11: Presenting results and ’Summary of findings’ tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane‐handbook.org.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al (editors). Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane‐handbook.org.
Skeggs LT, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. Journal of Experimental Medicine 1957;106(3):439‐53.
Wang Z, Wang X, Chen Z, Wang W, Zhu H, Chen W, et al. Hypertension control in community health centers across China: analysis of antihypertensive drug treatment patterns. American Journal of Hypertension 2014;27(2):252‐9.
Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Journal of the American Society of Hypertension 2007;1(4):264‐77.
White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. Journal of Clinical Hypertension 2010;12(10):765‐75.
Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GWK, et al. First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD008170.pub2]
